ArticleEmerging infectious diseases2026
Identification of Novel Recombinant Human Adenovirus Genotype B117 from Pediatric Cases, China.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During molecular surveillance of human adenoviruses (HAdVs) in children hospitalized with acute lower respiratory tract infections in Beijing, China, during 2014-2024, the most prevalent genotypes were HAdV-B114 (53.85%) and HAdV-B7 (27.18%). A novel recombinant genotype, HAdV-B117, was identified in 2 children <5 years of age with severe community-acquired pneumonia and serious complications. Genomic analysis revealed that HAdV-B117 arose from HAdV-B114 (P7H3F3) with the fiber gene from HAdV-B7. We observed amino acid substitutions and deletions in the pivotal regions of 3 major capsid proteins, and some were predicted to alter the protein structure. In vitro, the replication kinetics of HAdV-B117 were similar to those of HAdV-B3 and HAdV-B7. Clinical manifestations resembled severe pneumonia caused by HAdV-B3 or HAdV-B7. Both children recovered after treatment. The emergence of HAdV-B117 highlights the need for continuous genomic surveillance of HAdVs to detect novel recombinants with potential public health effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.